206 related articles for article (PubMed ID: 16640339)
1. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
Imamura S; Ichikawa T; Nishikawa Y; Kanzaki N; Takashima K; Niwa S; Iizawa Y; Baba M; Sugihara Y
J Med Chem; 2006 May; 49(9):2784-93. PubMed ID: 16640339
[TBL] [Abstract][Full Text] [Related]
2. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
Imamura S; Nishikawa Y; Ichikawa T; Hattori T; Matsushita Y; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2005 Jan; 13(2):397-416. PubMed ID: 15598561
[TBL] [Abstract][Full Text] [Related]
3. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
[TBL] [Abstract][Full Text] [Related]
4. CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas.
Imamura S; Kurasawa O; Nara Y; Ichikawa T; Nishikawa Y; Iida T; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2004 May; 12(9):2295-306. PubMed ID: 15080927
[TBL] [Abstract][Full Text] [Related]
5. The discovery of tropane-derived CCR5 receptor antagonists.
Armour DR; de Groot MJ; Price DA; Stammen BL; Wood A; Perros M; Burt C
Chem Biol Drug Des; 2006 Apr; 67(4):305-8. PubMed ID: 16629828
[TBL] [Abstract][Full Text] [Related]
6. Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists.
Shankaran K; Donnelly KL; Shah SK; Caldwell CG; Chen P; Finke PE; Oates B; MacCoss M; Mills SG; DeMartino JA; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Kwei G; Carella A; Carver G; Danzeisen R; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
Bioorg Med Chem Lett; 2004 Jul; 14(13):3589-93. PubMed ID: 15177481
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane.
Shah SK; Chen N; Guthikonda RN; Mills SG; Malkowitz L; Springer MS; Gould SL; Demartino JA; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Emini EA; MacCoss M
Bioorg Med Chem Lett; 2005 Feb; 15(4):977-82. PubMed ID: 15686896
[TBL] [Abstract][Full Text] [Related]
8. [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring.
Duan M; Aquino C; Ferris R; Kazmierski WM; Kenakin T; Koble C; Wheelan P; Watson C; Youngman M
Bioorg Med Chem Lett; 2009 Mar; 19(6):1610-3. PubMed ID: 19233649
[TBL] [Abstract][Full Text] [Related]
9. CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives.
Lu SF; Chen B; Davey D; Dunning L; Jaroch S; May K; Onuffer J; Phillips G; Subramanyam B; Tseng JL; Wei RG; Wei M; Ye B
Bioorg Med Chem Lett; 2007 Apr; 17(7):1883-7. PubMed ID: 17314043
[TBL] [Abstract][Full Text] [Related]
10. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.
Shen DM; Shu M; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
Bioorg Med Chem Lett; 2004 Feb; 14(4):935-9. PubMed ID: 15012997
[TBL] [Abstract][Full Text] [Related]
11. 1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
Barber CG; Blakemore DC; Chiva JY; Eastwood RL; Middleton DS; Paradowski KA
Bioorg Med Chem Lett; 2009 Feb; 19(4):1075-9. PubMed ID: 19171484
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.
Ernst J; Dahl R; Lum C; Sebo L; Urban J; Miller SG; Lundström J
Bioorg Med Chem Lett; 2008 Feb; 18(4):1498-501. PubMed ID: 18194864
[TBL] [Abstract][Full Text] [Related]
13. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
Shen DM; Shu M; Willoughby CA; Shah S; Lynch CL; Hale JJ; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
Bioorg Med Chem Lett; 2004 Feb; 14(4):941-5. PubMed ID: 15012998
[TBL] [Abstract][Full Text] [Related]
14. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
Seto M; Miyamoto N; Aikawa K; Aramaki Y; Kanzaki N; Iizawa Y; Baba M; Shiraishi M
Bioorg Med Chem; 2005 Jan; 13(2):363-86. PubMed ID: 15598559
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors.
Hu S; Gu Q; Wang Z; Weng Z; Cai Y; Dong X; Hu Y; Liu T; Xie X
Eur J Med Chem; 2014 Jan; 71():259-66. PubMed ID: 24316669
[TBL] [Abstract][Full Text] [Related]
16. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.
Shu M; Loebach JL; Parker KA; Mills SG; Chapman KT; Shen DM; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Salvo JD; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
Bioorg Med Chem Lett; 2004 Feb; 14(4):947-52. PubMed ID: 15012999
[TBL] [Abstract][Full Text] [Related]
17. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
[TBL] [Abstract][Full Text] [Related]
18. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
19. Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents.
Li B; Jones ED; Zhou E; Chen L; Baylis DC; Yu S; Wang M; He X; Coates JA; Rhodes DI; Pei G; Deadman JJ; Xie X; Ma D
Bioorg Med Chem Lett; 2010 Sep; 20(17):5334-6. PubMed ID: 20674358
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.
Skerlj R; Bridger G; Zhou Y; Bourque E; McEachern E; Langille J; Harwig C; Veale D; Yang W; Li T; Zhu Y; Bey M; Baird I; Sartori M; Metz M; Mosi R; Nelson K; Bodart V; Wong R; Fricker S; Mac Farland R; Huskens D; Schols D
Bioorg Med Chem Lett; 2011 Dec; 21(23):6950-4. PubMed ID: 22033460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
